



SOSEI ANNOUNCES COMPLETION OF EXERCISE OF STOCK ACQUISITION RIGHTS

Tokyo, Japan – 12 March 2007: Sosei Group Corporation (“Sosei”, TSE Mothers Index: 4565) a biopharmaceutical company, today announces the completion of the exercise of Stock Acquisition Rights (“SARs”), issued on 22 January 2007.

- | | |
|--------------------------------------|--|
| 1. Name of Stock Acquisition Rights: | Sosei Group Corporation,
Stock Acquisition Rights
(11 th Series Stock Acquisition Rights) |
| 2. Allotee: | Merrill Lynch Japan Securities Co., Ltd. |
| 3. To be paid (total amount): | 3,274,560,000 Yen |
| 4. Exercise of right (percentage): | 100% |
| 5. Number of total shares issued: | 18,000 shares |
| New shares : | 18,000 shares |
| Treasury stocks: | 0 shares |
| 6. Type of shares: | Common Shares |

Enquiries

Sosei Group Corporation

Tokyo: Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan
Hiroki MAEKAWA, Representative Executive Officer,
E-mail: hmaekawa@sosei.com Tel: **+81-3-5210-3399** Fax: +81-3-5210-3291

UK: John DAFFURN, SVP Corporate Development

E-mail: daffurnj@sosei.com Tel: **+44 (0)1799 532350** Fax: +44 1799 532351

Financial Dynamics

Julia Phillips

Tel: **+44 (0)207 831 3113**

The Trout Group Brandon Lewis

Thomas Fechtner

Tel: **+1 646-378-2915**

Tel: **+1 646-378-2931**

Notes for Editors:**About Sosei**

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit www.sosei.com